THE TRENDLINES GROUP LTD.
(Incorporated in Israel)
(Company Registration No. 513970947)

QUESTIONS AND ANSWERS PROVIDED BY THE TRENDLINES GROUP AHEAD OF UPCOMING AGM AND SGM

The Board of Directors of The Trendlines Group Ltd. ("**Trendlines**" or the "**Company**" and, together with its subsidiaries and associated companies, the "**Group**") wishes to address questions received from shareholders prior to the upcoming annual general meeting for its financial year ended 31 December 2025 (**"AGM"**) and the special general meeting (**"SGM"**) to be held on 16 April 2026. It is customary for shareholders to utilize an AGM and SGM to direct questions to the Company with respect to its recently published Annual Report 2025 or regarding the resolutions to be presented at meetings such as our AGM and the SGM.

As some questions received were similar or the same but worded differently, we have consolidated them and not repeated similar questions but made references to relevant answers.

Question 1
Resolution 1
To Chairperson of AGM 2026 Reference Extract of Chair's statement in Annual Report 2023:
1 Strategic transformation Plan: "In November 2022 we announced a strategic transformation plan. The plan outlined giving more attention to our advanced stage portfolio companies and helping those portfolio companies realise significant exits. In accordance with the transformation plan, our focus is wholly on developing our existing portfolio to maximise exit proceeds. As a result of this shift, we did not invest in new portfolio companies in FY2023."

a. **How many significant exits have been made after the first ten exits mentioned in SGX announcement dated 3/8/2023**
   Company's response: No exits have been executed since.
b. **Is it true that the company decided to cease further investment into existing portfolio companies.**
   Company's response: No, the Company continues to invest into our existing portfolio companies.
c. **Are the investments by the LH related companies in portfolio companies of Trendlines beneficial to the minority shareholders of Trendlines?**
   Company's response: LH has been very generous by investing alongside us in Trendlines' portfolio companies. Without their investment, done at an "arms-

length basis" (i.e. with no special benefits to LH, besides the shareholding rights as with any external investor), we may have had to close some of the companies. Additionally, the fact that the controlling shareholder of Trendlines agreed to invest in our portfolio companies has put us in a better position to bring external and strategic investors to the companies.

Question 2

a. **Investment by LH related companies I believe that allowing LH related companies to take shares in portfolio companies of Trendlines will transfer most of the profits out of Trendlines. Could you explain why such a deal was done with LH related companies?**
   Company's response: The investments made by LH related companies are not to the detriment of Trendlines. As with any external investor and start-up portfolio companies, these investments provide funds needed by the portfolio companies to reach development or commercialization milestones, which in turn increase their value. Also see answer in question 1 c.
b. **The company has 28 graduated incubator companies amounting to $71,865,000 as at 31/12/2025. Valuing the investment at 4.4 times based on historical exit value is $316,206,000. It's much higher if one uses 9.7 times return with an exit value of $697,090,500 I see no need to allow LH related companies to come in as Trendlines should unlock value from the 28 graduated incubator companies and reap the profits that rightly belong to Trendlines. The resolution to benefit LH related companies at the expense of Trendlines should be withdrawn.**
   Company's response: To clarify, there are no specific resolutions tabled at the AGM or SGM that will benefit LH related companies at the expense of Trendlines.
   1. Portfolio companies need funding to continue their development and survive what is commonly known as "the valley of death", i.e. the period where they have not yet reached fundable milestones and are in danger of not surviving if they don't get bridge funding.
   2. Trendlines, with its constrained resources and available capital, is not able to invest in every promising portfolio company. As a result, some companies may be closed due to insufficient funding.
   3. LH is able and willing to invest their own funds into these companies to inject them with cash. These investments help the portfolio companies stay afloat reducing the likelihood of impairment or write-offs.

Question 3

Resolution 2

The proposed increase of the company's registered share capital.

Clarifications of the proposal is requested as follows:

a. **Would the new share issues of the company be placement shares offered at a big discount to RNAV,? If so, would this be detrimental to the interests of the existing shareholders?**

Company's response: The request to increase the share capital of the company is not related to any specific new shares issue.
No new shares have been issued, besides those approved in the past (see SGM results from 6 August 2025), and will be issued on September 2026.
Notwithstanding the foregoing, If subsequent placements are conducted at more than 10% discount to the prevailing share price, the company will need shareholders' approval.

b. **Instead of raising funds via new shares, would proceeds from the sale of portfolio companies be adequate to meet any subsequent funding required by the company?**
Company's response: That is our plan, and we are always working towards those opportunities. Our main goal is to be able to fund further investments from earnings from exits. However, the Company continues to carefully manage the timing of exits against its liquidity requirements, as it must balance achieving optimal exit valuations while maintaining sufficient cash resources to support its portfolio companies in their development towards reaching their full potential to optimize exits.

c. **When can we see the earliest exits of the promising portfolio companies?**
Company's response: When such a situation arises, the Company will provide an update.

Question 4
Resolution 5

a. **How does the proposed CEO Exit Event Bonus Plan specifically protect minority shareholders from dilution if an "Exit Event" occurs at a valuation lower than the 2021-2022 highs?**
Company's response: By granting the CEO the option of an exit bonus, it is aligned with the interest of the shareholders. This is the biggest motivation for management to work towards the goals of exits. If there is no exit, there is no exit bonus.

b. **Clawback Provisions**: **Are there specific "malus" or "clawback" provisions in the Amended Compensation Policy if a credited "Exit Event" is later restructured or fails to meet the cash-receipt milestones?**
Company's response: No. But the exit bonus is based on cash receipt only and not based on contract for future earnings.

c. **Phytolon Master Supply Agreements (MSAs): Following the FDA regulatory milestone, is the Group's 25% stake in Phytolon contingent on the signing of a formal Master Supply Agreement with partners like Rich Products or DSM-Firmenich to trigger a valuation write-up?**
Company's response: The FDA approval itself does not trigger a valuation writeup. There are other future developments which may trigger such a valuation increase.

d. **Transition to Commercial Valuation: Based on the above question c, how will the Board reflect the transition from 'R&D' to 'Commercial Revenue' in the valuation of Trendlines' 25% stake? Will this milestone trigger a 'Fair Value' write-up in the HY2026 results, and if so, how does this align with the hurdle rates for the Resolution 5 CEO Bonus Plan?**
Company's response: If Phytolon moves successfully from R&D stage to commercialization stage, we expect that this development will be reflected in the valuation of Phytolon. However, an increase in the valuation of a portfolio company is not an exit event and therefore does not trigger an exit bonus.

BY ORDER OF THE BOARD
Haim Brosh
Executive Director and Chief Executive Officer
12 April 2026

---

*This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.*

The contact person for the Sponsor is Mr. Shervyn Essex, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.